18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
Luca Urso(University of Ferrara), Mirco Bartolomei(University of Ferrara), Corrado Cittanti(University of Ferrara), Marta Frapoli(University of Ferrara), Martina Rauso(University of Ferrara), Licia Uccelli(University of Ferrara), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Federica Lancia(University of Ferrara), Naima Ortolan(University of Ferrara), Laura Evangelista(Istituto Oncologico Veneto), Paolo Artioli(University of Padua)
Cited by 11
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240